{"DataElement":{"publicId":"6035128","version":"1","preferredName":"Laboratory Procedure Oncotype DX Breast Cancer Assay Stratification Score","preferredDefinition":"Numeric range of the Oncotype DX Breast Cancer Assay for classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","longName":"LAB_ONCODX_STRAT_SC","context":"CCTG","contextVersion":"1","DataElementConcept":{"publicId":"6035123","version":"1","preferredName":"Laboratory Procedure Oncotype DX Breast Cancer Assay Stratification","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen._The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","longName":"2543047v1.0:6035121v1.0","context":"CCTG","contextVersion":"1","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6035121","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Stratification","preferredDefinition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.:The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","longName":"C52159:C25689","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncotype DX Breast Cancer Assay","conceptCode":"C52159","definition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stratification","conceptCode":"C25689","definition":"The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F487D8E-49B0-31E8-E053-F662850A0F6F","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"ONEDATA","dateModified":"2017-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F487D8E-49C1-31E8-E053-F662850A0F6F","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"WINCHC","dateModified":"2019-11-22","changeDescription":"12/1/17 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6035125","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Score","preferredDefinition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"6035125v1.0","context":"CCTG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"5","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"11-17","valueDescription":"Eleven To Seventeen","ValueMeaning":{"publicId":"6035126","version":"1","preferredName":"Eleven To Seventeen","longName":"6035126","preferredDefinition":"A natural number greater than 10 and less than 12 and the quantity that it denotes.: Used as a function word to indicate direction, purpose, or movement.: A natural number greater than 16 and less than 18 and the quantity that it denotes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eleven","conceptCode":"C113425","definition":"A natural number greater than 10 and less than 12 and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Seventeen","conceptCode":"C113431","definition":"A natural number greater than 16 and less than 18 and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F487D8E-4A04-31E8-E053-F662850A0F6F","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F487D8E-4A1D-31E8-E053-F662850A0F6F","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"ONEDATA","dateModified":"2017-12-01","deletedIndicator":"No"},{"value":"0-10","valueDescription":"Zero To Ten","ValueMeaning":{"publicId":"6035127","version":"1","preferredName":"Zero To Ten","longName":"6035127","preferredDefinition":"A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.: Used as a function word to indicate direction, purpose, or movement.: A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zero","conceptCode":"C70430","definition":"A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ten","conceptCode":"C69122","definition":"A natural number greater than 9 and less than 11 and the quantity that it denotes: the sum of nine and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F487D8E-4A2B-31E8-E053-F662850A0F6F","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F487D8E-4A44-31E8-E053-F662850A0F6F","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"ONEDATA","dateModified":"2017-12-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6035124","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Score","preferredDefinition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.:A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C52159:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncotype DX Breast Cancer Assay","conceptCode":"C52159","definition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F487D8E-49D8-31E8-E053-F662850A0F6F","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"ONEDATA","dateModified":"2017-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F487D8E-49E9-31E8-E053-F662850A0F6F","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"WINCHC","dateModified":"2019-11-22","changeDescription":"12/1/17 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Oncotype DX score","type":"Preferred Question Text","description":"Oncotype DX score","url":null,"context":"CCTG"}],"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F48BDFE-B8A0-5285-E053-F662850ADFC8","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-01","modifiedBy":"WINCHC","dateModified":"2019-11-22","changeDescription":"12/1/17 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}